EGFR V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Up-front osimertinib provides clinical benefit for patients with non-small cell lung cancer (NSCLC) harboring EGFR V834L and L858R mutations. This targeted therapy approach improves outcomes in this specific patient population.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Epidermal growth factor receptor (EGFR) mutations are key drivers in non-small cell lung cancer (NSCLC).
- Specific co-mutations, such as V834L and L858R, present unique challenges in treatment selection.
- Targeted therapies have revolutionized NSCLC treatment, but optimal sequencing and upfront use are areas of ongoing research.
Purpose Of The Study
- To evaluate the clinical efficacy and benefit of initiating osimertinib treatment upfront in patients with NSCLC.
- To investigate the outcomes associated with EGFR V834L and L858R co-mutations in NSCLC patients treated with upfront osimertinib.
Main Methods
- Retrospective analysis of NSCLC patient data.
- Inclusion of patients with confirmed EGFR V834L and L858R co-mutations.
- Assessment of clinical benefit based on objective response rate, progression-free survival, and overall survival.
Main Results
- Upfront osimertinib demonstrated significant clinical benefit in the studied NSCLC cohort.
- Patients with EGFR V834L and L858R co-mutations experienced favorable responses to initial osimertinib therapy.
- The observed outcomes suggest a positive impact of early targeted intervention.
Conclusions
- Initiating osimertinib upfront is a beneficial strategy for NSCLC patients with EGFR V834L and L858R co-mutations.
- This approach warrants consideration in treatment guidelines for this specific molecular subtype of NSCLC.
- Further prospective studies are recommended to confirm these findings.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...